#Guillain-Barre Syndrome Market forecast
Text
#Guillain-Barre Syndrome Market#Guillain-Barre Syndrome Market size#Guillain-Barre Syndrome Market share#Guillain-Barre Syndrome Market trends#Guillain-Barre Syndrome Market analysis#Guillain-Barre Syndrome Market forecast
0 notes
Text
Human Immunoglobulin (pH4) for Intravenous Injection is Estimated to Witness High Growth Owing to Rising Prevalence of Neurological and Immunodeficiency Diseases
Human immunoglobulin (pH4) is a blood plasma derived product administered intravenously for treatment of various neurological and immunodeficiency diseases. It contains antibodies which help strengthen the body's natural defenses against infectious agents. The rising incidences of immune deficiency disorders like agammaglobulinemia and common variable immunodeficiency have inflated the demand for immunoglobulin therapy.
The global Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at US$ 17.5 billion in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023-2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Rising prevalence of neurological and immunodeficiency diseases is estimated to witness high growth. Neurological disorders pose a significant healthcare burden globally and afflict millions worldwide each year. conditions like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy require intravenous immunoglobulin as a mode of treatment. According to the World Health Organization, over 1 billion people suffer from some form of neurological disorder. The annual cost of neurological conditions in the U.S. alone is estimated to be over $800 billion. Thus, the growing cases of neurological diseases will spur demand for immunoglobulin therapy, acting as a high impact rendering driver for the market.
Porter’s Analysis
Threat of new entrants: Low barrier to entry due to availability of raw material and manufacturing process knowledge. However, high capital requirements for production facilities and strong brand loyalty towards existing players limits threat.
Bargaining power of buyers: Moderate bargaining power due to presence of substitutes. However, specialized production process results in inelastic demand.
Bargaining power of suppliers: High dependence on plasma suppliers limits bargaining power. Suppliers can charge higher prices or refuse supply during shortages.
Threat of new substitutes: Low threat as IgG products have no close substitute for treatment of certain immune disorders and deficiencies. Substitution requires regulatory approval and clinical trials.
Competitive rivalry: Intense competition between major players. Companies compete based on product quality, reliability of supply, price and brand reputation.
SWOT Analysis
Strength: Established production facilities and regulatory approvals. Diversified product portfolio to treat range of conditions.
Weakness: High capital intensity of production and vulnerability to plasma supply disruptions. Stringent regulatory norms increase compliance costs.
Opportunity: Expanding patient population and increased diagnosis rate in developing regions. New clinical indications can boost revenue streams.
Threats: Price controls and government reimbursement policies. Stringent import and export regulations across countries.
Key Takeaways
The global Human Immunoglobulin (pH4) for Intravenous Injection market is expected to witness high growth. The market is dominated by North America owing to high prevalence of immunodeficiency and autoimmune disorders. Rising healthcare spending and presence of major players in the US and Canada will drive the region's market share.
Europe is the second largest regional market led by countries such as Germany, UK and France. Higher acceptance of IgG therapies and supportive national health strategies supplement the regional growth. Key players operating in the Human Immunoglobulin (pH4) for Intravenous Injection market are CSL Behring, Grifols, Baxter, Octapharma, Kedrion, CNBG, Hualan Bio and BPL. These players acquire plasma from approved donors and fractionate to produce standard and specialized IgG formulations.
0 notes
Text
Acute Flaccid Myelitis Market by Treatment Type (Pharmacological Treatment, Physical & Occupational Therapy, Plasmapheresis, and Others) - Global Outlook & Forecast 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, global acute flaccid myelitis market is expected to register a revenue CAGR of 3.2% during the forecast period.
Acute Flaccid Myelitis Market Fundamentals
Acute flaccid myelitis (AFM) is a life-threatening illness that appears like polio and was first identified in unusual clusters in California in 2012 and Colorado in 2014. With hundreds of cases recorded in Europe, Asia, Australia, Africa, North America, and South America, AFM is now recognized as a widespread condition. Recent AFM is thought to have been mostly caused by epidemic enteroviral infection, notably enterovirus D68 infection. Cases typically occur in geographic clusters in temperate climates and follow a clear seasonal-biennial pattern. Young children are most often affected by AFM, characterized by an abrupt onset of flaccid weakness in one or more limbs and abnormalities in the grey matter of the spinal cord. Additional muscles may be affected include the extraocular, respiratory, bulbar, and trunk muscles. Clinical signs of other acute weakness-causing conditions, such as Guillain-Barre syndrome, demyelinating myelitis, and other infectious myelitis, may resemble those of AFM.
Get Free Sample PDF including full TOC, Tables and Figures, and Available customizations: https://www.growthplusreports.com/inquiry/request-sample/acute-flaccid-myelitis-market/9278
Less than 15% of incidents of AFM in adults (more frequently in the immunocompromised) occur, with AFM in adults perhaps needing to be more reported or recognized. AFM is mostly a pediatric condition. There may be a small preference for men. Most AFM patients experience a prodromal sickness that includes a fever and respiratory symptoms (such as a cough, rhinorrhea, pharyngitis, or a disease that resembles asthma). Vomiting and diarrhea are less common gastrointestinal complaints.
Headache, stiffness in the neck, or a return of fever can occur together with the development of neurological symptoms. Pain in the afflicted limb(s), neck, or lower back often precedes limb weakening in patients. Flaccid weakness usually affects one or more limbs and is asymmetrical, with a preference for the upper limbs and proximal muscle groups. In addition to limb weakness, over 30% of patients exhibit motor deficits localized to the brainstem's cranial nerve motor nuclei. These deficits are largely bulbar and facial weakness, with extraocular muscle weakness occurring less frequently.
The most effective diagnostic procedure for AFM is an MRI of the spinal cord. The distinctive feature of AFM is spinal cord grey matter T2 hyperintensity. When examined axially, early acute phase lesions impact the whole grey matter of the spinal cord. They are often confluent and poorly delineated, with varied degrees of surrounding white matter involvement and edema. Grey matter lesions in the spinal cord are often longitudinally widespread.
Acute Flaccid Myelitis Market Dynamics
The acute flaccid myelitis market is growing due to rising awareness, increasing surveillance initiatives, identification and reporting of AFM cases. The number of reported cases of AFM has increased as medical professionals and public health organizations have become more cautious in finding and diagnosing the condition. For instance, Acute Flaccid Myelitis Association aims to increase public understanding and support for this disease. They also offer assistance to parents, caregivers, and those who are experiencing AFM symptoms. Their funding is used to meet the requirements of the patients. They utilize donations to pay for therapies, treatments, and equipment not covered by insurance for families. More than 90% of donations are used immediately to meet the critical medical requirements of AFMA grant candidates. Additionally, the federal government has noticed the illness due to the advocacy efforts of AFM-affected families, the Acute Flaccid Myelitis Association (AFMA), and medical professionals who treat patients with the condition. Senator Kirsten Gillibrand, for example, proposed $1 billion in funding for AFM research in 2018.
Accurate and rapid diagnosis of AFM patients has been made possible by improved methods for diagnosis, including laboratory testing and enhanced imaging equipment. This is likely because more information is available on illness and its prevalence. For instance, according to the National Library of Medicine 2021, 96% of documented AFM cases in the USA 2018 were hospital admissions, with 58% going to an intensive care unit. Early management's cornerstone is supportive care and vigilant monitoring targeted toward possibly developing critical problems. Moreover, according to the Centers for Disease Control & Prevention, as of June 2, 2023, twenty reports of patients under investigation (PUIs) had been made, and three of those reports had been confirmed. Since August 2014, when CDC started monitoring AFM, there have been 727 confirmed cases. Since then, the CDC has conducted extensive investigations into cases. In 2014, 2016, and 2018, there was a rise in AFM incidence, particularly involving young children.
However, AFM does not currently have a particular therapy other than symptomatic assistance. Research is still being done to understand the illness better and provide therapies. There are scientific possibilities and needs for further study in AFM, according to a 2020 article in Clinical Infectious Diseases. The long-term outcomes of AFM and juvenile transverse myelitis were compared in a 2020 study published in BMC Neurology.
Acute Flaccid Myelitis Market Ecosystem
The global acute flaccid myelitis market is analyzed from the following perspectives by treatment type and region.
Acute Flaccid Myelitis by Treatment Type
Based on the treatment type, the global acute flaccid myelitis market is segmented into pharmacological treatment, physical & occupational therapy, plasmapheresis, and others.
There haven't been any regulated investigations of medical AFM therapies. To increase the body's resistance to viruses, intravenous immunoglobulin (IVIG) can be administered. Steroids and plasma exchange are two common medications used to treat transverse myelitis (TM), and they have been tested in AFM with varying degrees of success.
Early commencement of physical and occupational therapy (PT and OT) is essential for successfully treating AFM. Both occupational and physical therapy are crucial. Children frequently attend treatment sessions for weeks or months. For the greatest results, children with AFM need to be treated by a multidisciplinary team. Even if full muscle function cannot be recovered, early intervention may improve everyday functioning and restore function to the damaged limbs.
Acute Flaccid Myelitis by Region
Based on the treatment type, the global acute flaccid myelitis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
The number of instances of poliomyelitis dropped to 209 worldwide in 2014 due to poliovirus vaccinations, with nonpolio enteroviruses being the main cause of new cases of acute flaccid myelitis. Acute flaccid myelitis cases have been observed most recently during enterovirus D68 outbreaks in North America and Europe, indicating the possibility of another non-polio enterovirus linked to acute flaccid myelitis. North America had an outbreak of enterovirus D68 infections in the autumn of 2014, the majority of which were accompanied by symptoms of the upper respiratory tract. The authors describe a cluster of three individuals who had acute flaccid myelitis in Alberta, Canada, during an enterovirus D68 epidemic, with enterovirus D68 found in two of these patients.
The number of reports of acute flaccid paralysis cases has increased in the United Kingdom (UK), with many cases being identified as AFM. Unexpected clusters of AFM were first recorded in the US in 2014. Clinically, various individuals often have poliomyelitis-like paralysis, affecting one or more limbs, with no discernible sensory loss and distinctive grey matter abnormalities on MRI. A prevalent EV virus known as EV-D68, which appeared to circulate biennially in late summer and fall and was connected to severe acute respiratory and neurological disease between 2014 and 2016 in Europe, Asia, and North America, was temporally associated with an increase in AFM cases.
Acute Flaccid Myelitis Market Competitive Landscape
Some of the prominent market players in the global acute flaccid myelitis market include,
Baxter International Inc.
Octapharma AG
Behring GmbH
BioScrip Inc.
Pfizer Inc.
Novartis AG
AstraZeneca
GSK Plc.
Cipla Inc.
Acute Flaccid Myelitis Strategic Development
In August 2019, to comprehend the uncommon polio-like virus that affects children, the National Institute of Allergy and Infectious Diseases (NIAID) granted $10 million over five years for natural history research on acute flaccid myelitis (AFM).
Visit our report store at https://www.growthplusreports.com/report-store
#data analytics#healthcare#pharmasales#occupational therapy#physical therapy#rare disease#pediatric neurology
0 notes
Text
0 notes
Text
0 notes
Text
0 notes
Text
0 notes
Text
Intravenous Immunoglobulin Market Size Hit $18.67Bn, Globally, by 2028 Growing at 7.6% CAGR | Exclusive Report by The Insight Partners
The Insight Partners published latest research study on Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type (IgG, IgA, IgM, IgE, and IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others).
#Intravenous Immunoglobulin Market#Intravenous Immunoglobuli#Global Intravenous Immunoglobulin Market
1 note
·
View note
Text
Global Immunoglobulin Market Expected to Advance at 6.77% CAGR by 2028
Triton Market Research presents the Global Immunoglobulin Market report sectioned by Type (IgM, IgD, IgG, IgE, IgA), Delivery Mode (Intravenous, Intramuscular, Subcutaneous), Application (Hypogamma Globulienemia, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, Idiopathic Thrombocytopenic Purpura, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy, Primary Immunodeficiency Diseases, Other Applications), End-user (Homecare, Hospital and Clinics), Sales Channel (Specialty Pharmacy, Hospital Pharmacy, Other Sales Channels), and Geography ( Europe, North America, Latin America, Middle East and Africa, Asia-Pacific).
The report further discusses the Market Summary, Industry Outlook, Impact of COVID-19, Key Insights, Porter’s Five Forces Analysis, Market Attractiveness Index, Vendor Scorecard, Key Market Strategies, Drivers, Challenges, Opportunities, Competitive Landscape, Research Methodology and Scope, Global Market Size, Forecasts & Analysis (2022-2028).
Request free sample:
https://www.tritonmarketresearch.com/reports/immunoglobulin-market#request-free-sample
The market report by Triton shows that the global immunoglobulin market is expected to grow at a CAGR of 6.77% during the forecast period 2022-2028.
Immunoglobulins refer to antibodies naturally produced by the body to fight infections and diseases. Generated by plasma cells, they are glycoprotein molecules acting as the critical component of the immune system. They recognize and bind to antigens like viruses and bacteria while aiding in their destruction.
The immunoglobulin market saw growth during as well as the post-COVID-19 pandemic. The market is further expected to grow during the forecasted year due to the driving factors like the increase in the geriatric population, the prevalence of immunodeficiency diseases, autoimmune disorders and increasing research and development activities. However, one of the major factors that restrict the market growth is the high cost of immunoglobulin therapy, which is directly associated with the type of delivery method used and the site of care. Another factor is the high risk of side effects due to immunoglobulin use.
Globally, the Asia-Pacific is expected to become the fastest-growing region in the immunoglobulin market. The rapid rise in the prevalence of different diseases, the rise in the aging population, and the research and development across the region are key factors expected to boost the market’s growth during the forecast period. Further, several market players are launching or are expected to launch innovative products, thereby supporting the immunoglobulin market’s growth.
The leading companies excelling in the immunoglobulin market are Biotest AG, Grifols SA, CSL Behring, Octapharma AG, Bio Products Laboratory, Shanghai Raas Blood Products Co Ltd, Sanquin Plasma Products BV, Adma Biologics, Kamada Ltd, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Sanquin Plasma Products BV, Shanghai Raas Blood Products Co Ltd, Takeda Pharmaceutical Company Limited, Kedrion Biopharma, LFB Group, and China Biologic Products Inc.
The products in the biotechnology industry are subject to multiple standards, regulations, and approvals from the regulatory authorities that can challenge the new market player. Thus, these factors lower the threat of new entrants to the existing players. Moreover, there is a high threat to the intensity of competitive rivalry due to industry fragmentation. Additionally, prominent players have strengthened and expanded their customer base and geographical footings through strategic initiatives such as product launches, collaborations, joint ventures, and investments.
Contact Us:
Phone: +44 7441 911839
#Immunoglobulin Market#immunoglobulin#lifesciences#healthcare#diagnostic#biotechnology#triton market research#market research reports#market research report
0 notes
Text
Immunoglobulin Market Clinical Research Analysis 2022-2030
Increasing geriatric population along with improved immunoglobulin production are key factors driving the growth of the immunoglobulin market.
The Immunoglobulin Market is expected to grow at a CAGR of 5.4% from 2020-2030, according to a new research report by Next Move Strategy Consulting.
Immunoglobulins are produced by plasma cells and other lymphocyte to protect the body from diseases. They act as antibodies and support the immune system against viruses, bacteria and other disease causing agents. The growth of the immunoglobulin market is majorly driven by factors such as increasing geriatric population and rising number of hemophilic patients. Also, improved production of immunoglobulins due to the adoption of advanced technology for the extraction and introduction of enhanced purification processes in recent times, has been significantly contributing to the growth of the immunoglobulin market. However, strict government policies along with risk of side effects are anticipated to hinder the market growth during the forecast period to some extent.
On the basis of product, the market is segmented into IGG, IGA, IGM, IGE and IGD. On the basis of application, the market is segmented into Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITP), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain Barre Syndrome, and Others. On the basis of mode of delivery, the market is segmented into intravenous and subcutaneous. Intravenous is sub segmented into 5% concentration, 10% concentration and others. Subcutaneous is sub segmented into 16.5% concentration, 20% concentration and others. Based on geography the market is segmented into North America, Europe, Asia Pacific and RoW.
Access Full Description of this report at: -
Geographically, North America holds the lion share of the global immunoglobulin market owing to factors such as presence of developed economies as well as increasing prevalence of haemophilia in this region. However, Asia Pacific is expected to show exponential growth within the forecast period. This is attributed to factors such as rising geriatric population, prevalence of inflammatory diseases, and increasing accessibility to healthcare facilities in this region.
According to the report, some the key players in the immunoglobulin market are CSL Ltd., Baxter international Inc., Octapharma AG, Grifols S.A, LFB group, Kedrion Biopharma Inc., China Biologics Products, Inc., Biotest AG, Shire (Baxalta), and Bayer AG among others.
Key Insights:
Current emerging trends and opportunities are extensively analysed in immunoglobulin market report.
The forecast of the immunoglobulin market comes along with additional information associated with opportunities, restrains and key drivers in the market.
The report Immunoglobulin Market – is segmented by product, application, mode of delivery and geography.
Request sample copy of this report at:-
About Next Move Strategy Consulting
Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.
For more insights, please visit, https://www.nextmsc.com
0 notes
Link
Guillain-Barre Syndrome Market focuses on the market status, growth forecast, growth opportunities, upcoming challenges and key players.
0 notes
Text
Intravenous Immunoglobulin (IVIg) Market expected to witness relatively significant growth in 2027
Intravenous Immunoglobulin (IVIg) Market Overview :
The intravenous immunoglobulin (IVIg) market is projected to grow by US$10,485.86 Million by 2027 rapidly at a CAGR of 6.30% throughout the forecast period. Developing healthcare infrastructure as well as increasing demand for alternative therapies drive the global intravenous immunoglobulin (IVIg) market. These key growth drivers have incredibly helped the intravenous immunoglobulin (IVIg) market and are estimated to boost the growth. Analysts studying the intravenous immunoglobulin (IVIg) market have also shared growth projections in the intravenous immunoglobulin (IVIg) market research report and have suggested intravenous immunoglobulin (IVIg) market-based companies to develop growth strategies. LAck of awareness about therapies as well as slow economic growth in developing countries are the challenges that companies across the intravenous immunoglobulin (IVIg) market could face. The details covered in the intravenous immunoglobulin (IVIg) market report cover all the aspects of the industry.
Get customized Sample with complete Toc, @ https://www.marketresearchfuture.com/sample_request/3137
Intravenous Immunoglobulin (IVIg) Market Segmentation :
The global intravenous immunoglobulin (IVIg) market has been segmented based on type and applications. On the basis of type, the market for intravenous immunoglobulin (IVIg) is segmented based on IgD, IgE, IgG, IgM, and IgA. Additionally, the market on the basis of applications, is segmented into Guillain-Barre syndrome, hypogammaglobulinemia, immunodeficiency diseases, ITP, Kawasaki disease, multifocal motor neuropathy, myasthenia gravis, primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy (CIDP), and others.
Factors like increasing R&D funding and rising healthcare expenditure propel the intravenous immunoglobulin (IVIg) market growth. The intravenous immunoglobulin (IVIg) market performance has also been studied. The intravenous immunoglobulin (IVIg) market report provides analysis of past and current trends. In addition to this, the intravenous immunoglobulin (IVIg) market report offers detailed analysis of type and applications segments. The market segmental analysis provided in the intravenous immunoglobulin (IVIg) market research report offers crucial details about the intravenous immunoglobulin (IVIg) market based on the data and forecasts till 2027.
Intravenous Immunoglobulin (IVIg) Market Regional Overview :
The intravenous immunoglobulin (IVIg) market report covers companies functional in the intravenous immunoglobulin (IVIg) market spread across regional markets of North America, Europe, Asia-Pacific (APAC), and the rest of the world. The regional analysis of the intravenous immunoglobulin (IVIg) market can be found in the market research report. The North American intravenous immunoglobulin (IVIg) market has several key players functioning in the United States, Canada, and Mexico. Europe has companies in the intravenous immunoglobulin (IVIg) market across Germany, France, Spain, Italy, and the United Kingdom. The intravenous immunoglobulin (IVIg) market of the Middle East, Africa, and other regions has also been studied by analysts. A detailed analysis of the intravenous immunoglobulin (IVIg) market across India, China, and Japan in the Asia-Pacific region is also available for further study.
Intravenous Immunoglobulin (IVIg) Market Competitive Landscape :
The intravenous immunoglobulin (IVIg) market is corroborated by developing healthcare infrastructure. The population growth as well as increasing demand of intravenous immunoglobulin (IVIg) market based solutions also accelerate the market growth. However, the intravenous immunoglobulin (IVIg) market can be affected due to low levels of awareness as well as lack of advanced infrastructure. The intravenous immunoglobulin (IVIg) market research report covers all such factors assisting companies in the intravenous immunoglobulin (IVIg) market to improve their plans and portfolio. The intravenous immunoglobulin (IVIg) market research report also provides company profiles of major businesses. The intravenous immunoglobulin (IVIg) market report highlights crucial details about organizations operating across North America, Europe, Asia-Pacific (APAC), and the rest of the world regional markets. The details available in the intravenous immunoglobulin (IVIg) market report cover company strategies, revenue, company size, and mergers and acquisitions in the intravenous immunoglobulin (IVIg) market. New entrants as well as established organizations can use the data from intravenous immunoglobulin (IVIg) market report to further plan their strategies.
Intravenous Immunoglobulin (IVIg) Industry News :
A research presented at the 2020 American Society of Hematology Virtual Symposium on the impact of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab (Darzalex) showed that hypogammaglobulinemia was pretty ubiquitous throughout daratumumab therapy, indicating a role for IVIG, particularly in patients with chronic infections.
Get Premium Research Report, Inclusive of COVID-19 Impact Analysis, Find more information @ https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137
#IntravenousImmunoglobulin(IVIg)Market#IntravenousImmunoglobulinMarketSize#IntravenousImmunoglobulin(IVIg)MarketForecast#IntravenousImmunoglobulin(IVIg)MarketStudy#IntravenousImmunoglobulin(IVIg)MarketTrends
1 note
·
View note
Text
Guillain-Barre Syndrome Market Size, Share, Trends Analysis & Competition through 2023
Guillain-Barre Syndrome Market Highlights
The increasing prevalence of the Guillain-Barre syndrome, the increasing geriatric population, and the increasing occurrence of chikungunya are expected to be some of the major drivers for the market growth during the forecast period. However, factors such as lack of awareness, the absence of effective treatment, and low per capita healthcare expenditures in the middle- and low-income countries are estimated to restrain the market growth during the projected period.
Request Free Sample @ https://www.marketresearchfuture.com/sample_request/5741
Guillain-Barre Syndrome Market Key Players
The key players in the global Guillain-Barre Syndrome market are Grifols (Spain), Baxter (U.S.), CSL Behring (U.S.), Akari Therapeutics Plc (U.S.), ANNEXON, INC. (U.S.), Curavac (Europe), Hansa Medical (Sweden), Vitality Biopharma (U.S.), Covidien Limited (Republic of Ireland), Natus Medical Inc. (U.S.), Electrical Geodesics Inc. (U.S.), and others.
Guillain-Barre Syndrome Market Segmentation
The global Guillain-Barre Syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user. On the basis of type, the market is segmented into Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP), Miller Fisher Syndrome (MFS), Acute Motor Axonal Neuropathy (AMAN), and others. On the basis of diagnosis, the market is categorized into lumbar puncture, electromyography, nerve conduction studies, and others. The electromyography segment is sub-segmented into intramuscular electromyography, surface electromyography, and others. On the basis of treatment, the market is segmented into plasmapheresis, medication, physical therapy, hydrotherapy, and others. The medication segment is sub-segmented into privigen intravenous, gammagard liquid injection, flebogamma DIF intravenous, bivigam intravenous, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, and others.
Guillain-Barre Syndrome Market Regional Analysis
America dominates the global Guillain-Barre Syndrome market. This can be attributed to the presence of a well-developed healthcare sector, huge patient population, and rising per capita healthcare expenditure. Moreover, the changing lifestyle and rising per capita healthcare expenditure boost the market. Europe stands second in the global Guillain-Barre Syndrome market owing to the availability of funds for research and a huge patient population. Europe is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the market while Eastern Europe is estimated to be the fastest growing region. Asia Pacific is projected to be the fastest growing market. This can be attributed to the presence of a huge patient population and developing economies such as India and China within the region. On the other hand, the Middle East and Africa holds the least share in the global Guillain-Barre Syndrome Market owing to the presence of poor economies, lack of healthcare services, and stringent government policies, especially in the African region. A majority of the regions of the Middle East and Africa are held by the Middle East.
Access Report Details @ https://www.marketresearchfuture.com/reports/guillain-barre-syndrome-market-5741
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Market Research Future
+1 646 845 9312
Email: [email protected]
#Guillain-Barre Syndrome Market#Guillain-Barre Syndrome Market Size#Guillain-Barre Syndrome Market Share#Guillain-Barre Syndrome Market Growth#Guillain-Barre Syndrome Market Analysis#Guillain-Barre Syndrome Market Forecast
0 notes
Link
“Guillain-Barre Syndrome Market ”gives detailed outlook by Type, by Application, by Segmentation and Regional Forecasts.
0 notes
Text
Intravenous Immunoglobulin Market 2023 | Business Opportunity, Growth Strategies & Forecast Report By 2028
The Intravenous Immunoglobulin Market Report, in its latest update, highlights the significant impacts and the recent strategical changes under the present socio-economic scenario. The Intravenous Immunoglobulin industry growth avenues are deeply supported by exhaustive research by the top analysts of the industry. The report starts with the executive summary, followed by a value chain and marketing channels study. The report then estimates the CAGR and market revenue of the Global and regional segments.
Base Year: 2021
Estimated Year: 2022
Forecast Till: 2023 to 2028
The report classifies the market into different segments based on type and product. These segments are studied in detail, incorporating the market estimates and forecasts at regional and country levels. The segment analysis is helpful in understanding the growth areas and potential opportunities of the market.
Get | Download FREE Sample Report of Global Intravenous Immunoglobulin Market @ https://www.decisiondatabases.com/contact/download-sample-17991
A special section is dedicated to the analysis of the impact of the COVID-19 pandemic on the growth of the Intravenous Immunoglobulin market. The impact is closely studied in terms of production, import, export, and supply.
The report covers the complete competitive landscape of the Worldwide Intravenous Immunoglobulin market with company profiles of key players such as:
Baxter international Inc.
Grifols S.A.
Kedrion BioPharma Inc.
Octapharma AG
Biotest AG
China Biologics Products Ltd.
CSL Limited
LFB Group
Want to add more Company Profiles to the Report? Write your Customized Requirements to us @ https://www.decisiondatabases.com/contact/get-custom-research-17991
Intravenous Immunoglobulin Market Analysis by Type:
Hypogammaglobulinemia
CIDP
Immunodeficiency diseases
Congenital AIDS
Chronic Lymphocytic Leukemia
Myasthenia Gravis
Multifocal Motor Neuropathy
ITP
Kawasaki Disease
Guillain-Barre Syndrome
Intravenous Immunoglobulin Market Analysis by Route Of Administration:
Intravenous
Subcutaneous
Intravenous Immunoglobulin Market Analysis by Geography:
North America (USA, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South-East Asia, Rest of Asia-Pacific)
Latin America (Brazil, Argentina, Peru, Chile, Rest of Latin America)
The Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa, Rest of the Middle East and Africa)
Key questions answered in the report:
What is the expected growth of the Intravenous Immunoglobulin market between 2023 to 2028?
Which application and type segment holds the maximum share in the Global Intravenous Immunoglobulin market?
Which regional Intravenous Immunoglobulin market shows the highest growth CAGR between 2023 to 2028?
What are the opportunities and challenges currently faced by the Intravenous Immunoglobulin market?
Who are the leading market players and what are their Strengths, Weakness, Opportunities, and Threats (SWOT)?
What business strategies are the competitors considering to stay in the Intravenous Immunoglobulin market?
Purchase the Complete Global Intravenous Immunoglobulin Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-17991
About Us:
DecisionDatabases.com is a global business research report provider, enriching decision-makers, and strategists with qualitative statistics. DecisionDatabases.com is proficient in providing syndicated research reports, customized research reports, company profiles, and industry databases across multiple domains. Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors. We provide intellectual, precise, and meaningful data at a lightning speed.
For more details:
DecisionDatabases.com
E-Mail: [email protected]
Phone: +91 90 28 057900
Web: https://www.decisiondatabases.com/
#Intravenous Immunoglobulin Market#Intravenous Immunoglobulin Market Report#Intravenous Immunoglobulin Market Size#Intravenous Immunoglobulin Market Share#Intravenous Immunoglobulin Market Growth
0 notes
Text
Intravenous Immunoglobulin Market Size Estimated to Reach $17.1 Billion by 2026
Intravenous Immunoglobulin Market size is estimated to reach $17.1 billion by 2026, growing at a CAGR of 7.5% during the forecast period 2021-2026. Intravenous Immunoglobulins are antibodies that are part of the blood's plasma and are produced naturally by the body's immune system. Intravenous Immunoglobulin (IVIG) is a therapy treatment for patients with various immunodeficiency diseases and bleeding disorders. These are glycoproteins made by the immune system of healthy people for fighting infections. It works in different ways to decrease inflammation in the body. Rise in the adoption of glycoproteins for the treatment of various immunodeficiency diseases, growing demand for immunoglobulin G (IgG) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia, and increasing awareness about the efficiency of intravenous immunoglobulins as a treatment option are the factors that are set to drive the growth of the Intravenous Immunoglobulin Market for the period 2021-2026.
Intravenous Immunoglobulin Market Segment Analysis-By Product Type
The Intravenous Immunoglobulin Market based on the Product Type can be further segmented into Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), Immunoglobulin E (IgE), and Immunoglobulin D (IgD). The Immunoglobulin G (IgG) segment held the largest share in 2020 owing to its ability to control infection of body tissues and to protect the body from infection by binding many kinds of pathogens, such as viruses and fungi.
The rise in the applications of Immunoglobulin G (IgG) for the treatment of hypogammaglobulinemia is driving the growth of the Intravenous Immunoglobulin Market. The Immunoglobulin A (IgA) segment is estimated to be the fastest growing segment with a CAGR of 8.3% over the period 2021-2026. This growth is owing to its ability to inhibit bacterial adhesion to epithelial cells and neutralize both bacterial and virus toxins. Immunoglobulin A (IgA) also acts as the first line of defense in the resistance against infection.
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=506919
Report Price: $ 5900 (Single User License)
Intravenous Immunoglobulin Market Segment Analysis-By Application
The Intravenous Immunoglobulin Market based on the Application can be further segmented into Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Inflammatory Myopathies, Guillain-Barre Syndrome, Specific Antibody Deficiency, and Others. The Hypogammaglobulinemia segment held the largest share in 2020 and is also estimated to be the fastest growing segment with a CAGR of 8.4% over the period 2021-2026. This growth is owing to the factors such as the growing prevalence of hypogammaglobulinemia across the world and the rise in the research and development activities by the key players to developed advanced therapies for the treatment of hypogammaglobulinemia.
The rise in the adoption of intravenous immunoglobulins for the treatment of hypogammaglobulinemia is driving the growth of the Intravenous Immunoglobulin Market. The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) segment held the second largest share in 2020 owing to the factors such as increase in the prevalence of diabetes mellitus and growing awareness among the consumers about the benefits of minimally invasive and user-friendly procedures for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Intravenous Immunoglobulin Market Segment Analysis-By Geography
North America held the largest share with 29% of the overall market in 2020. The growth in this segment can be attributed to the factors such as increase in the demand for immunoglobulin G (IgG) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and rise in the research and development activities by the key players to developed advanced therapies for the treatment of hypogammaglobulinemia.
The rise in the adoption of glycoproteins for the treatment of various immunodeficiency diseases is driving the growth of the Intravenous Immunoglobulin Market. Asia-Pacific segment is estimated to be the fastest growing segment over the period 2021-2026. The growth in this segment is owing to the factors such as growing awareness about the efficiency of intravenous immunoglobulins as a treatment option and the rise in the adoption of advanced technologies pertaining to immunoglobulin production.
Intravenous Immunoglobulin Market Drivers
Rise in the Adoption of Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Intravenous Immunoglobulins are increasingly being used for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) owing to its associated benefits such as minimally invasive and user-friendly treatment options. These glycoproteins act as a critical part of the immune response by specifically binding to particular antigens, which is one of the major factors driving the growth of the Intravenous Immunoglobulin Market.
Increase in the Prevalence of Immunodeficiency Diseases and Bleeding Disorders
With an increase in the prevalence of immunodeficiency diseases and bleeding disorders across the world, there is an increase in the awareness among consumers about the efficiency of intravenous immunoglobulins as a treatment option. The key players are also focusing on developed advanced intravenous immunoglobulins for the treatment of various immunodeficiency diseases, which is further propelling the growth of the Intravenous Immunoglobulin Market.
Download Sample Report @ https://www.industryarc.com/pdfdownload.php?id=506919
Intravenous Immunoglobulin Market Challenges
High Cost of Intravenous Immunoglobulin Therapy
The government of several nations and other organizations are increasing their initiatives to enhance awareness among people about immunodeficiency diseases and the efficiency of various intravenous immunoglobulins as a treatment option. However, the high cost of Intravenous Immunoglobulin therapy is one of the major factors that is estimated to reduce the growth of the Intravenous Immunoglobulin Market.
Intravenous Immunoglobulin Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Intravenous Immunoglobulin Market. Key companies of this market include Baxter International Inc, Takeda Pharmaceuticals, Bayer Healthcare, AscellaHealth, Kedrion Biopharma, Grifols, Biotest AG, Octapharma AG, LFB group, and Kedrion Biopharma Inc among others.
Partnerships/Product Launches
In November 2020, AscellaHealth has launched its Intravenous Immunoglobulin (IVIG) Medication Therapy to support the aim of the Immune Deficiency Foundation (IDF) and to enhance patient care and cost management approaches.
In June 2020, Grifols has launched its hyperimmune immunoglobulin for the treatment of infections that are applied to healthcare emergencies like the Ebola outbreak and to prevent infections in cases of accidental exposure to infectious agents associated with autoimmune diseases.
In April 2020, Kedrion Biopharma has entered into a partnership with Kamada for the Development, and Distribution of Intravenous Immunoglobulin to make a significant impact for patients in need during the pandemic.
Key Takeaways
Geographically, North America Intravenous Immunoglobulin Market accounted for the highest revenue share in 2020 and it is poised to dominate over the period 2021-2026 owing to the growing adoption of glycoproteins for the treatment of various immunodeficiency diseases.
The rise in the applications of Immunoglobulin G (IgG) for the treatment of hypogammaglobulinemia is driving the Immunoglobulin G (IgG) segment. However, the high cost of intravenous immunoglobulin therapy is one of the major factors that is said to reduce the growth of the Intravenous Immunoglobulin Market.
Detailed analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Intravenous Immunoglobulin Market report.
Related Reports :
A. Injectable Drug Delivery Market
https://www.industryarc.com/Report/1255/injectable-drug-delivery-market-analysis.html
B. Monoclonal Antibodies Market
https://www.industryarc.com/Report/16114/monoclonal-antibodies-market.html
For more Lifesciences and Healthcare Market reports, please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.
0 notes
Last Seen Blogs
cyberthecreator
Cyber, The Dumpster Queen
knikknax
Mauricheo
palmplazaworld
PalmplaZa
theprimeministeracey
Live the live you are about to Explore